Canaccord Genuity Group Boosts Teladoc Health (NYSE:TDOC) Price Target to $11.00

Teladoc Health (NYSE:TDOC) had its price objective lifted by equities research analysts at Canaccord Genuity Group from $10.00 to $11.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s target price suggests a potential upside of 23.40% from the stock’s previous close.

Several other research analysts have also issued reports on the company. Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Barclays decreased their price objective on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Bank of America boosted their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Finally, Citigroup increased their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.73.

Teladoc Health Stock Down 8.2%

Shares of NYSE TDOC opened at $8.91 on Tuesday. The firm has a fifty day simple moving average of $7.96 and a two-hundred day simple moving average of $6.50. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $1.61 billion, a PE ratio of -9.19 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The company had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. During the same period in the previous year, the firm posted ($0.53) EPS. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Equities analysts expect that Teladoc Health will post -0.92 earnings per share for the current year.

Insider Activity

In related news, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the sale, the insider owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the sale, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 39,195 shares of company stock worth $299,058. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

A number of hedge funds have recently added to or reduced their stakes in TDOC. Creative Planning grew its stake in Teladoc Health by 7.7% during the third quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock valued at $159,000 after acquiring an additional 1,462 shares in the last quarter. Versant Capital Management Inc lifted its stake in Teladoc Health by 33.3% in the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock worth $70,000 after purchasing an additional 2,052 shares in the last quarter. Syon Capital LLC lifted its stake in Teladoc Health by 19.1% in the 4th quarter. Syon Capital LLC now owns 14,140 shares of the health services provider’s stock worth $99,000 after purchasing an additional 2,264 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Teladoc Health by 8.2% during the 4th quarter. ProShare Advisors LLC now owns 32,532 shares of the health services provider’s stock valued at $228,000 after purchasing an additional 2,457 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 2,810 shares in the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.